Introduction
Although surgical resection is recognized as the primary treatment for patients with advanced gastric carcinoma, overall survival rates in such patients are not yet satisfactory [1, 2] . Neoadjuvant chemotherapy (NAC) or postoperative adjuvant chemotherapy with anticancer agents with a high effi cacy rate has thus been an essential adjunct to improve the clinical outcome of patients undergoing surgical resection [3] . A dihydropyrimidine dehydrogenase (DPD)-inhibitory fl uoropyrimidine (DIF) is widely recognized as the most effective fi rst-line chemotherapeutic agent for NAC or postoperative adjuvant chemotherapy in gastric carcinoma [4] [5] [6] [7] ; however, bona fi de factors predictive of sensitivity to this agent remain to be elucidated. S-1 (TS-1; Taiho Pharmaceutical, Tokyo, Japan) is a novel oral DIF developed by Shirasaka et al. [8, 9] . It is designed to provide high and prolonged serum concentrations of 5-fl uorouracil (5-FU) with minimal toxicity. S-1 contains tegafur (a masked compound of 5-FU) and two types of enzyme inhibitors, 5-chloro-2, 4-dihydropyrimidine and potassium oxonate, in a molar ratio of 1 : 0.4 : 1.
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In the present study, we examined OPRT levels in gastric carcinoma tissue and in normal gastric mucosa and evaluated the relationship between OPRT levels and clinicopathological variables and the correlation between OPRT levels and TS and DPD in carcinoma tissue.
Patients, materials, and methods

Patients and tissue specimens
A total of 138 patients with advanced gastric carcinoma gave their written informed consent for the use of the specimens in the study. The study was approved by the Institutional Ethics Review Board for Human Investigation at Fujita Health University. A total of 97 gastric carcinoma tissue specimens and 65 normal gastric mucosa samples were obtained from 97 of the 138 patients with gastric carcinoma, who underwent surgical resection at the fi rst Educational Hospital, Fujita Health University School of Medicine. Gastric carcinoma specimens and normal gastric mucosa were simultaneously obtained from 24 patients. All specimens were collected immediately after surgical resection and were immersed in liquid nitrogen and frozen at −80 °C until analyzed.
The patients with gastric carcinoma consisted of 32 women and 65 men whose mean age was 67.2 ± 11.5 years. The clinicopathological characteristics of the 97 patients with gastric carcinoma are summarized in Table  1 . The clinicopathological factors are expressed in accordance with the Japanese Classifi cation of Gastric Carcinoma [14] .
Enzyme-linked immunosorbent assay (ELISA) for measurement of tissue OPRT levels
A recently established sandwich-type ELISA [11] [12] [13] was used to measure OPRT levels in gastric carcinoma tissue and normal gastric mucosa. We showed previously that a signifi cant correlation existed between OPRT levels and OPRT enzymatic activity [11] ; therefore, the OPRT level determined by the ELISA directly refl ects enzymatic activity. The ELISA is described in detail elsewhere [11] . Briefl y, the assay was performed with anti-OPRT-A and anti-OPRT-C antibodies as the catcher and the tracer, respectively. Fifty microliters of 5.0 mg/ml anti-OPRT-C antibody, dissolved in 0.1 M carbonate buffer (pH 9.6), was coated onto an enzyme immunoassay (EIA) plate (Nalge Nunc International; Rochester, NY, USA) at 4 °C for 16 h. After a washing with distilled water, blocking was performed with SabilCoat (SurModics; Eden Prairie, MN, USA) at room temperature for 60 min. Protein extracts of cancer tissue samples were diluted and adjusted to a fi nal concentration of 1 mg/ml. One hundred milliliters of protein extract per well was added, and the plates were incubated at room temperature for 60 min. The wells were then washed fi ve times with phosphate-buffered saline (PBS). One hundred milliliters of peroxidase-labeled anti-OPRT-A antibody per well was added, and the plates were incubated at room temperature for 30 min. After the wells were washed with PBS seven times, 100 ml of orthophenylene diamine (OPD) dissolved in substrate buffer (0.05 M citrate buffer, 0.01% H 2 O 2 , 1 mM ethylenediamine tetraacetic acid [EDTA]) solution was added, and the plates were incubated at room temperature for 30 min. The reaction was stopped by the addition of 0.5 N sulfate solution. Absorbance at 492 nm was measured with a plate reader (Spectramax 3400PC; Molecular Devices, Tokyo, Japan). Protein extract derived from the human breast cancer cell line MDA-MB-435S, in which OPRT protein was previously quantifi ed by immunoblotting, was used as the standard. The OPRT level was determined by comparison with OPRT levels in the standard samples.
Immunohistochemical expression of the OPRT molecule
A total of 97 gastric carcinoma tissues were subjected to immunohistochemical staining with a polyclonal antibody against the human recombinant OPRT molecule. The production and characterization of the antibody are described in detail elsewhere [12] . Immunohistochemical staining was performed on formalin-fi xed, paraffi n-embedded sections of surgically resected specimens of gastric carcinoma, as described by Kamoshida et al. [15] . The sections were deparaffi nized with xylene and rehydrated with graded ethanol solutions. Endogenous peroxidase was inactivated by 0.03% hydrogen peroxide in methanol for 30 min. Rabbit polyclonal antibody against OPRT (diluted 1 : 500; Taiho Pharmaceutical, Tokushima, Japan) was added, and the sections were incubated overnight at room temperature. With the use of the universal immuno-enzyme polymer method, Histofi ne Simple Stain MAX-PO (Nichirei, Tokyo, Japan) was employed as a second-layer reagent. The reaction products were visualized in 50 mg/dl 3, 3′-diaminobenzidine tetrahydrochloride solution containing 0.003% hydrogen peroxide. The specifi city of OPRT staining was previously confi rmed in preabsorption experiments [15] . Our previous study showed that OPRT immunoreactivity was observed in almost all tissue components at various intensities [15] . Therefore, the intensity of immunoreactivity in carcinoma tissue was compared with that of the surrounding normal gastric epithelium, and the immunostained sections were classifi ed into two groups: positive (stronger than the normal epithelium) and negative (comparable with or weaker than the normal epithelium). All sections were reviewed independently by two pathologists blinded to all clinical and pathological information.
Measurement of TS and DPD in human gastric carcinoma tissue
Tissue concentrations of TS and DPD in 46 gastric carcinoma tissues were measured by using sandwich ELISAs established previously [16, 17] . The precise methods of each ELISA are described in detail elsewhere [17] .
Statistical analysis
Differences in OPRT levels between gastric carcinoma tissue and normal gastric mucosa were evaluated by using Student's t-test and the Mann-Whitney test. Correlations between OPRT levels in carcinoma tissue and in normal gastric epithelium were evaluated by using correlation coeffi cients. The signifi cance of the correlations was evaluated with Fischer's Z-transformation. All statistical calculations were performed by using Statview version 5.0 (Abacus Concepts, Berkeley, CA, USA). P < 0.05 was considered statistically signifi cant.
Results
OPRT levels in gastric carcinoma tissue and normal gastric mucosa
Levels of OPRT in gastric carcinoma tissue and normal gastric mucosa, stratifi ed by clinicopathological variables, are summarized in Table 1 . OPRT levels were signifi cantly higher in well-differentiated type carcinomas than in poorly differentiated carcinomas and were higher in localized than in infi ltrative types. OPRT levels were also signifi cantly higher in cases with medullary type stroma than in cases with scirrhous type stroma. OPRT levels did not differ signifi cantly according to T, ly, v, n, P, or M factors, or pathological stage. Distributions and histograms of OPRT levels in gastric carcinoma tissues and in normal gastric mucosa are shown in Fig. 1 A and Fig. 1 B, respectively. The mean OPRT level in gastric carcinoma tissues was 5.4 ± 3.6 ng/ mg protein and that in normal gastric mucosa was 3.9 ± 4.7 ng/mg protein (P < 0.05 by Mann-Whitney test). The highest OPRT values in gastric carcinoma tissue and in normal gastric mucosa were 16.0 ng/ml and 19.9 ng/ml, respectively. No correlation was found between the OPRT level in gastric carcinoma tissue and that in normal gastric mucosa obtained simultaneously from the same patients ( Fig. 2 ; r = 0.218; not signifi cant [NS] by Fischer's Z-transformation). 
Immunohistochemical reactivity to OPRT
The immunohistochemical expression of OPRT in gastric carcinoma was examined in 97 cases. OPRT was immunohistochemically expressed not only in cancer cells but also in non-neoplastic gastric mucosa and in intestinal metaplastic cells (Fig. 3) . Nonepithelial cells, such as neutrophils, lymphocytes, and smooth muscle cells, also stained positively. OPRT expression was positive in 25 of 97 (25.8%) and negative in 72 of 97 (74.2%) gastric carcinoma cases, respectively. The intensity of the immunohistochemical staining was stronger in intestinal-type gastric carcinoma than in diffuse-type gastric carcinoma (Fig. 3) . The OPRT level (mean ± SD) of the cases with positive OPRT expression was 7.5 ± 2.5 ng/ mg protein and that of the cases with negative OPRT expression was 4.7 ± 3.6 ng/mg protein (P < 0.0001 by Mann-Whitney test).
Correlation of OPRT level with TS and DPD levels in gastric carcinoma
No signifi cant correlations were found between OPRT levels and TS levels or between OPRT levels and DPD levels (Fig. 4 A, B) . The correlation coeffi cients were −0.017, and −0.354, respectively (not signifi cant by Fischer's Z-transformation).
Discussion
The primary aims of the present study were to examine OPRT levels in both gastric carcinoma tissue and normal gastric mucosa, to examine the correlation between OPRT levels and clinicopathological variables, and to examine the correlation between levels of OPRT and those of TS and DPD. Our results showed that OPRT levels were higher in patients with well-differentiated or localized-type carcinomas than in those with poorly differentiated or invasive types. There was no signifi cant correlation between OPRT levels and clinicopathological variables. OPRT levels were signifi cantly higher in gastric carcinoma tissue than in normal gastric mucosa. These results, along with our previous observations [11] , suggest that OPRT plays an important role in the activation of fl uoropyrimidines in carcinoma tissues and that the OPRT level in gastric carcinoma tissues is an independent variable that can predict sensitivity to dihydropyrimidine dehydrogenase-inhibitory fl uoropyrimidines (DIFs). Evidence for a signifi cant anticancer effect of S-1 was shown by the recent interim analysis of adjuvant chemotherapy for gastric cancer with S-1 (ACTS-GC), randomized phase III multi-institutional clinical trial, as presented at the 2007 Gastrointestinal Cancers Symposium (ASCO-GI). The analysis showed that postoperative adjuvant chemotherapy with S-1 alone significantly improved postoperative survival in patients with stage II/III gastric cancer who had undergone D2 gastrectomy. Although the overall anticancer effect was signifi cant, anticancer effects in individual cases were not uniform, and a certain number of patients showed chemoresistance to S-1-based chemotherapy [18] . Thus, a novel factor that can predict response to S-1-based chemotherapy is needed.
OPRT is a 5-FU-anabolyzing enzyme that plays a primary role in initial phosphorylation in human cancers [10, 19] . Orotate phosphoribosyltransferase (EC 2.4.2.10) and orotidine-5′-monophosphate decarboxylase (EC 4.1.1.23) are involved in the reactions of adding ribose-5′-phosphate to orotic acid and in the decarboxylation of orotidine-5′-monophosphate, respectively. In vivo, OPRT catalyzes the fi nal two steps in de-novo pyrimidine synthesis [20] . Three distinct pathways by which 5-FU is activated into nucleotide have been identifi ed [19] : (1) fl uorouridine (FUR) 5-FU, activated in vivo by OPRT and catalyzed by uridine phosphorylase with ribose-1-phosphate (Rib-1-P); and (3) indirect conversion to fl uorodeoxyuridine monophosphate (FdUMP) by 2′-deoxy-5-fl uorouridine, catalyzed by thymidine phosphorylase with deoxy-Rib-1-P. Among these pathways, the direct pathway converting 5-FU to FUMP has been shown to be predominant in tumor tissues [19, 21] , which indicates that OPRT activity is the main rate-limiting step in the phosphorylation of 5-FU. OPRT activity is therefore likely to be associated with the anticancer effects of 5-FU. The present study demonstrated that OPRT levels were high in well-differentiated-type carcinoma and localized-type carcinoma, and in patients with medullary stroma. Despite the association of OPRT with histological characteristics, however, OPRT levels were unrelated to pathological stage, which is in contrast with the results of a previous report of gastric carcinoma [22] . Mizutani et al. [23] reported that the enzyme activity of OPRT in bladder carcinoma was associated with clinical stage and histological grade. Our results, however, refl ect the biological characteristics of gastric carcinoma. Because it has been shown that histological type and the type of local infi ltration are associated with prognosis in gastric carcinoma [24, 25] , the association of OPRT with clinicopathological characteristics should be accounted for in survival analysis after neoadjuvant or adjuvant chemotherapy.
In the present study, OPRT levels in gastric carcinoma tissue were signifi cantly higher than those in normal gastric mucosa, and this was particularly significant in intestinal-type gastric carcinoma. One possible explanation for this fi nding is that because OPRT is the enzyme related to pyrimidine synthesis in vivo, higher OPRT levels would be expected in tissues with high cell proliferative activity [26] . In fact, immunohistochemical analysis has shown that OPRT is also expressed in normal gastrointestinal epithelial cells [15] . Previously reported immunohistochemical analysis also showed that the intensity of immunoreactivity of OPRT in cancer cells was stronger than that in their normal counterparts; thus, the results of the present study support the immunohistochemical expression of OPRT in carcinoma tissue and normal gastric mucosa. Therefore, it seems that fl uoropyrimidine is phosphorylated mainly in carcinoma tissues, and this indicates that OPRT plays an important role in activating fl uoropyrimidine in carcinoma tissue.
In the present study, no signifi cant correlation existed between OPRT levels and levels of TS or DPD in gastric carcinoma tissues. We previously reported no correlation of OPRT levels with thymidine phosphorylase [11] . Because OPRT, TS, and thymidine phosphorylase have been recognized as possible factors that determine sensitivity to DIF, OPRT may be used to determine sensitivity to DIF independently of TS or thymidine phosphorylase.
In summary, although the OPRT level was high in well-differentiated and localized-type carcinomas, OPRT levels were not correlated with the pathological stage of gastric carcinoma. OPRT levels were significantly higher in gastric carcinoma tissue than in normal gastric mucosa, but no correlation existed between OPRT levels in gastric carcinoma tissue and those in normal gastric mucosa. OPRT levels were not correlated with levels of TS or DPD, which suggests that OPRT is a novel factor that is independent of other previously known enzymes related to 5-FU metabolism. Along with our previous observations, suggesting that there is a signifi cant association between the OPRT level and sensitivity to DIF [11] , these results suggest that the OPRT level in gastric carcinoma tissues is an independent variable that can predict sensitivity to DIFs. Given the results of the present preclinical study, further clinical study regarding the prognostic signifi cance of OPRT levels in gastric carcinoma tissues in patients with advanced gastric carcinoma undergoing neoadjuvant and/or adjuvant chemotherapy with a DIF is required to confi rm the value of OPRT for predicting sensitivity to DIF.
